163 related articles for article (PubMed ID: 38492861)
21. Identification of Nonfunctional Alternatively Spliced Isoforms of STING in Human Acute Myeloid Leukemia.
Boda AR; Liu AJ; Castro-Pando S; Whitfield BT; Molldrem JJ; Al-Atrash G; Di Francesco ME; Jones P; Ager CR; Curran MA
Cancer Res Commun; 2024 Mar; 4(3):911-918. PubMed ID: 38477596
[TBL] [Abstract][Full Text] [Related]
22. STING pathway as a cancer immunotherapy: Progress and challenges in activating anti-tumor immunity.
Tabar MMM; Fathi M; Kazemi F; Bazregari G; Ghasemian A
Mol Biol Rep; 2024 Apr; 51(1):487. PubMed ID: 38578532
[TBL] [Abstract][Full Text] [Related]
23. Tumor microenvironment-responsive DNA-based nanomedicine triggers innate sensing for enhanced immunotherapy.
Li J; Han X; Gao S; Yan Y; Li X; Wang H
J Nanobiotechnology; 2023 Oct; 21(1):382. PubMed ID: 37858171
[TBL] [Abstract][Full Text] [Related]
24. Activating Innate Immunity by a STING Signal Amplifier for Local and Systemic Immunotherapy.
Song W; Song SJ; Kuang J; Yang H; Yu T; Yang F; Wan T; Xu Y; Wei ST; Li MX; Xiong Y; Zhou Y; Qiu WX
ACS Nano; 2022 Oct; 16(10):15977-15993. PubMed ID: 36190834
[TBL] [Abstract][Full Text] [Related]
25. Targeting STING for cancer immunotherapy: From mechanisms to translation.
Huang R; Ning Q; Zhao J; Zhao X; Zeng L; Yi Y; Tang S
Int Immunopharmacol; 2022 Dec; 113(Pt A):109304. PubMed ID: 36252492
[TBL] [Abstract][Full Text] [Related]
26. STING-activating nanoparticles normalize the vascular-immune interface to potentiate cancer immunotherapy.
Wang-Bishop L; Kimmel BR; Ngwa VM; Madden MZ; Baljon JJ; Florian DC; Hanna A; Pastora LE; Sheehy TL; Kwiatkowski AJ; Wehbe M; Wen X; Becker KW; Garland KM; Schulman JA; Shae D; Edwards D; Wolf MM; Delapp R; Christov PP; Beckermann KE; Balko JM; Rathmell WK; Rathmell JC; Chen J; Wilson JT
Sci Immunol; 2023 May; 8(83):eadd1153. PubMed ID: 37146128
[TBL] [Abstract][Full Text] [Related]
27. Targeting acute myeloid leukemia through multimodal immunotherapeutic approaches.
Przespolewski AC; Portwood S; Wang ES
Leuk Lymphoma; 2022 Apr; 63(4):918-927. PubMed ID: 34818963
[TBL] [Abstract][Full Text] [Related]
28. Activating cGAS-STING pathway for the optimal effect of cancer immunotherapy.
Li A; Yi M; Qin S; Song Y; Chu Q; Wu K
J Hematol Oncol; 2019 Apr; 12(1):35. PubMed ID: 30935414
[TBL] [Abstract][Full Text] [Related]
29. Multifunctional hybrid exosomes enhanced cancer chemo-immunotherapy by activating the STING pathway.
Cheng L; Zhang P; Liu Y; Liu Z; Tang J; Xu L; Liu J
Biomaterials; 2023 Oct; 301():122259. PubMed ID: 37531777
[TBL] [Abstract][Full Text] [Related]
30. STING activation reprograms tumor vasculatures and synergizes with VEGFR2 blockade.
Yang H; Lee WS; Kong SJ; Kim CG; Kim JH; Chang SK; Kim S; Kim G; Chon HJ; Kim C
J Clin Invest; 2019 Jul; 129(10):4350-4364. PubMed ID: 31343989
[TBL] [Abstract][Full Text] [Related]
31. Supramolecular Cyclic Dinucleotide Nanoparticles for STING-Mediated Cancer Immunotherapy.
Xu L; Deng H; Wu L; Wang D; Shi L; Qian Q; Huang X; Zhu L; Gao X; Yang J; Su Y; Feng J; Zhu X
ACS Nano; 2023 Jun; 17(11):10090-10103. PubMed ID: 37253192
[TBL] [Abstract][Full Text] [Related]
32. Plasmacytoid dendritic cells orchestrate innate and adaptive anti-tumor immunity induced by oncolytic coxsackievirus A21.
Müller LME; Holmes M; Michael JL; Scott GB; West EJ; Scott KJ; Parrish C; Hall K; Stäble S; Jennings VA; Cullen M; McConnell S; Langton C; Tidswell EL; Shafren D; Samson A; Harrington KJ; Pandha H; Ralph C; Kelly RJ; Cook G; Melcher AA; Errington-Mais F
J Immunother Cancer; 2019 Jul; 7(1):164. PubMed ID: 31262361
[TBL] [Abstract][Full Text] [Related]
33. Manganese-enriched photonic/catalytic nanomedicine augments synergistic anti-TNBC photothermal/nanocatalytic/immuno-therapy via activating cGAS-STING pathway.
Zheng Y; Chen J; Song XR; Chang MQ; Feng W; Huang H; Jia CX; Ding L; Chen Y; Wu R
Biomaterials; 2023 Feb; 293():121988. PubMed ID: 36580716
[TBL] [Abstract][Full Text] [Related]
34. Biomineralized MnO
Deng Z; Xi M; Zhang C; Wu X; Li Q; Wang C; Fang H; Sun G; Zhang Y; Yang G; Liu Z
ACS Nano; 2023 Mar; 17(5):4495-4506. PubMed ID: 36848115
[TBL] [Abstract][Full Text] [Related]
35. Discovery of IACS-8803 and IACS-8779, potent agonists of stimulator of interferon genes (STING) with robust systemic antitumor efficacy.
Ager CR; Zhang H; Wei Z; Jones P; Curran MA; Di Francesco ME
Bioorg Med Chem Lett; 2019 Oct; 29(20):126640. PubMed ID: 31500996
[TBL] [Abstract][Full Text] [Related]
36. Intratumoral immunotherapy using a TLR2/3 agonist, L-pampo, induces robust antitumor immune responses and enhances immune checkpoint blockade.
Lee WS; Kim DS; Kim JH; Heo Y; Yang H; Go EJ; Kim JH; Lee SJ; Ahn BC; Yum JS; Chon HJ; Kim C
J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35764365
[TBL] [Abstract][Full Text] [Related]
37. RIG-I-based immunotherapy enhances survival in preclinical AML models and sensitizes AML cells to checkpoint blockade.
Ruzicka M; Koenig LM; Formisano S; Boehmer DFR; Vick B; Heuer EM; Meinl H; Kocheise L; Zeitlhöfler M; Ahlfeld J; Kobold S; Endres S; Subklewe M; Duewell P; Schnurr M; Jeremias I; Lichtenegger FS; Rothenfusser S
Leukemia; 2020 Apr; 34(4):1017-1026. PubMed ID: 31740809
[TBL] [Abstract][Full Text] [Related]
38. Multi-Immune Agonist Nanoparticle Therapy Stimulates Type I Interferons to Activate Antigen-Presenting Cells and Induce Antigen-Specific Antitumor Immunity.
Levy ES; Chang R; Zamecnik CR; Dhariwala MO; Fong L; Desai TA
Mol Pharm; 2021 Mar; 18(3):1014-1025. PubMed ID: 33541072
[TBL] [Abstract][Full Text] [Related]
39. Impaired B cell immunity in acute myeloid leukemia patients after chemotherapy.
Goswami M; Prince G; Biancotto A; Moir S; Kardava L; Santich BH; Cheung F; Kotliarov Y; Chen J; Shi R; Zhou H; Golding H; Manischewitz J; King L; Kunz LM; Noonan K; Borrello IM; Smith BD; Hourigan CS
J Transl Med; 2017 Jul; 15(1):155. PubMed ID: 28693586
[TBL] [Abstract][Full Text] [Related]
40. Systematic preclinical evaluation of CD33-directed chimeric antigen receptor T cell immunotherapy for acute myeloid leukemia defines optimized construct design.
Qin H; Yang L; Chukinas JA; Shah N; Tarun S; Pouzolles M; Chien CD; Niswander LM; Welch AR; Taylor N; Tasian SK; Fry TJ
J Immunother Cancer; 2021 Sep; 9(9):. PubMed ID: 34531250
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
